A Double-blind Multicenter Two-arm Randomized Placebo-controlled Phase-III Clinical Study to Evaluate the Effectiveness and Safety of Thymosin α1 as an Add-on Treatment to Existing Standard of Care Treatment in Moderate-to-severe COVID-19 Patients

BACKGROUND: From an epidemic outbreak, coronavirus disease-2019 (COVID-19) has quickly developed. Thymosin α1 (Tα1) has the ability to boost the T-cell numbers, support T-cell differentiation, maturation, and reduce cell apoptosis. In this study, we have investigated the efficacy and safety of Tα1 i...

Descripción completa

Detalles Bibliográficos
Autores principales: Shetty, Adarsh, Chandrakant, Nirhali Sonali, Darnule, Rahul Ashok, Manjunath, BG, Sathe, Prachee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Jaypee Brothers Medical Publishers 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9363815/
https://www.ncbi.nlm.nih.gov/pubmed/36042753
http://dx.doi.org/10.5005/jp-journals-10071-24298

Ejemplares similares

Ejemplares similares